



Cretan tea (*Origanum dictamnus* L.) as a functional beverage: investigation on antiglycative and carbonyl trapping activities

| | |
|-------------------------------|--|
| Journal: | <i>Food & Function</i> |
| Manuscript ID | FO-ART-12-2017-001930.R1 |
| Article Type: | Paper |
| Date Submitted by the Author: | n/a |
| Complete List of Authors: | Maietta, Mariarosa; University of Pavia, Department of Drug Sciences Colombo, Raffaella; University of Pavia, Drug Sciences Department Corana, Federica; University of Pavia, Centro Grandi Strumenti Papetti, Adele ; University of Pavia, Drug Sciences Department |
| | |

Food & Function

2015 Impact Factor: 2.676

www.rsc.org/foodfunction



FULL PAPER SUBMISSION

Linking the chemistry & physics of food with health & nutrition



The following article has been submitted to *Food & Function* for consideration as a **Full Paper**.

Food & Function provides a unique venue for physicists, chemists, biochemists, nutritionists and other food scientists to publish work at the interface of the chemistry, physics and biology of food. The journal focuses on food and the functions of food in relation to health; this includes the following:

- Physical properties and structure of food
- Chemistry of food components
- Biochemical and physiological actions
- Nutritional aspects of food

Articles relating purely to food analysis will not be published in *Food & Function* - these can be published in our sister journal, *Analytical Methods*.

***Food & Function* Full Papers must describe high impact science that will be of benefit to the community and are judged according to originality, quality of scientific content and contribution to existing knowledge. Only the most significant papers (top 25%) will be considered for acceptance.**

Good quality work, however competently researched and reported, should not be recommended for publication if it does not meet the criteria with regards to highly original and immediate interest to the broad food research community.

Authors are encouraged to provide a succinct and relevant introduction to the research and to consider the use of the Electronic Supplementary Information for additional material.

Thank you for your effort in reviewing this submission. It is only through the continued service of referees that we can maintain both the high quality of the publication and the rapid response times to authors. We would greatly appreciate if you could review this paper in **14 days**. Please let us know if that will not be possible.

Once again, we appreciate your time in serving as a reviewer. To acknowledge this, the Royal Society of Chemistry offers a **25% discount** on our books: <http://pubs.rsc.org/bookshop>. Please also consider submitting your next manuscript to *Food & Function*.

Best wishes

Philippa Hughes
Executive Editor

Professor Kevin Croft
Editor-in-Chief

RESPONSE TO REVIEWERS' COMMENTS:

We revised our manuscript according to the comments and suggestions of Reviewers. We highlighted in yellow the additions and/or changes in the revised manuscript

REVIEWER REPORT(S):

Referee: 1

Comments to the Author

General comment:

The manuscript entitled Cretan tea (*Origanum dictamnus* L.) as a functional beverage: investigation on antiglycative and carbonyl trapping activities is very interesting and the data presented here is of relevance to the field of functional food composition.

The work is well structured and well-presented and the issue has been addressed with sufficient scientific rigour, in my opinion this manuscript can be considered for publication with only a few minor revisions.

Specific Comments:

-The antiglycative activity is investigated with different in vitro test, the authors the authors should better explain the reason.

We thank the Reviewer for the comment. We better explain the reason in the text (Introduction section: lines 87-93).

-In the description of RP-HPLC-DAD-ESI- MS the authors reported the mass fragment with amu and Da. I suggest using only a measurement unit.

We thank the Reviewer for the comment. We used only Da as measurement unit (see lines 267, 268, 270, 275, 296, 302)

- I suggest to number the figures and table in the order of text presentation

We thank the Reviewer for the comment. We changed the order of the Figures in the text

Referee: 2

Comments to the Author

Manuscript entitled "Cretan tea (*Origanum dictamnus* L.) as a functional beverage: investigation on antiglycative and carbonyl trapping activities" by the authors Mariarosa Maietta, Raffaella Colombo, Federica Corana, Adele Papetti was aimed to investigate usefulness of herbal tea in the reduction of non-enzymatic protein glycation and in the scavenging of free radicals.

In my opinion, the Manuscript presented in this form has scientific merit and should be accepted for the publication in Food & Function after minor revisions. In the following some recommendations and comments are given.

Introduction

Page 5 ...and several polyphenols were characterized in the aqueous extract (hydroxycinnamic acids and catechins) 17, 25-28 and in different polar solvent extracts (phenolic acids and flavonoids).11, 14,16, 18, 23, 28,29

Authors should be more specific when citing published results. For example, cite ref no 17 for

hydroxybenzoic acids, hydroxycinnamic acids, and flavonoids. Other possibility is to cite a review on the work done in this field.

We thank the Reviewer for the comment. We better specified references related to each class of polyphenols (see page 4, lines 73-75).

Section 2.4.

Page 8 ... (or positive control AG) or phosphate buffer (blank). Unclear sentence.

Aminoguanidine (AG) is known to be an antiglycative agent and commonly used as standard (positive control).

Section 3.2.

Page 20 ...The antiglycative activity is generally correlated to the polyphenolic composition of the extracts. In particular, previous structure-activity studies indicated that flavones are able to exhibit stronger inhibitory effects when compared to flavonols, flavanones, and isoflavones. Reference is needed for this paragraph.

We thank the Reviewer for the comment. We added references 72 (see page 28, lines 674-675).

...The composition of dittany infusion rich in apigenin, luteolin, kaempferol, and also hydroxycinnamic derivatives could justify the high antiglycative activity registered.

Correct to hydroxycinnamic acid derivatives

We thank the Reviewer for the comment. We corrected the text (line 456)

Authors stated the main objectives of the research were to study the chemical composition of the beverage and to evaluate its effect on the generation of early glycation products and AGEs. In my opinion it would be advisable to try to give some comments on the structure features of the polyphenols identified in the structure-activity (antiglycative) relationship sense.

As stated we tested the activity of the whole infusion and identified its chemical composition. At this stage it is hard to hypothesize any correlation between the structures of the identified compounds and the activity of the infusion because it would be necessary to test each single compound.

Literature

Correct the names in the reference No 41 ...M. M. Natić, D. C. Dabić, M. M. Fotirić Akšić, M. Ljubojević and Z. Tešić, to M. M. Natić, D. Č. Dabić, M. M. Fotirić Akšić, M. Ljubojević, Ž. Tešić

We thank the Reviewer for the comment. We corrected the Reference

Table 1 Please reorganize table by putting ($\mu\text{mol g}^{-1}$) into the column. Statistical test on the antioxidant activity is not relevant.

We thank the Reviewer for the comment. Table 1 was modified

Table 2 Correct the names of the compounds in the table... e.g. Kampferol

We thank the Reviewer for the comment. Table 2 was corrected



Dipartimento di Scienze del Farmaco
Università degli Studi di Pavia

1

2 January 9th, 2018

3

4 Dear Editor,

5 We revised our manuscript according to the suggestion and comments of the Reviewers'. Please, find the
6 new version with the response to the Reviewers' comments.

7 I am looking forward to hearing from you soon.

8 Best regards,

9

10

11 Dr. Adele Papetti, PhD

12 Corresponding Author



13 Dipartimento di Scienze del Farmaco – sede amministrativa Viale Taramelli 12 –27100 PAVIA

14 Tel. +39-0382-987358-7362 Fax +39-0382-422975 e-mail: emdip07@unipv.it

15 indirizzo web: <http://chifar.unipv.eu/site/home.html>

16 Sezione di Chimica e Tecnologia Farmaceutiche - Viale Taramelli 12 –27100 PAVIA

17 Sezione di Farmacologia - Viale Taramelli 14 –27100 PAVIA

18

19

20

21

22

23 **Cretan tea (*Origanum dictamnus* L.) as a functional beverage: investigation on antiglycative**
24 **and carbonyl trapping activities**

25 Mariarosa Maietta^a, Raffaella Colombo^a, Federica Corana^b, Adele Papetti^{a*}

26 ^aDepartment of Drug Sciences, University of Pavia, Pavia, Italy

27 ^bCentro Grandi Strumenti, University of Pavia, Via Bassi 21, 27100, Pavia, Italy

28

29

30 *Corresponding author: e-mail: adele.papetti@unipv.it

31 Tel.: +39 0382 987863

32 Fax: +39 0382 422975

33 Abstract

34 Accumulation of advanced glycation end products (AGEs) *in vivo* is associated with many chronic
35 disorders such as diabetes, renal failure, aging, and Alzheimer's disease. The aim of this study was
36 to expand the knowledge about the functional properties of *Origanum dictamnus* L. beverage
37 (Cretan tea) by an investigation about the inhibitory effects on the formation of AGEs and the
38 capacity to trap dicarbonyl compounds. Dittany infusion was characterized in its polyphenolic
39 composition by RP-HPLC-DAD-ESI-MSⁿ and twenty compounds were detected. Antiglycative
40 property was evaluated by *in vitro* BSA-sugars (glucose, fructose, and ribose) and BSA-
41 methylglyoxal (MGO) assays, formation of Amadori products and dicarbonyl compounds tests,
42 direct glyoxal (GO) and MGO trapping capacity. The infusion showed the highest inhibitory effect
43 on the formation of dicarbonyl compounds and of AGEs (activity values range 72-100%) and only a
44 weak effect on the formation of Amadori products, indicating that the antiglycative action occurred
45 primarily during the last two phases of the non-enzymatic glycation reaction. These activities are
46 partially correlated with the antioxidant/antiradical activity, as demonstrated by the scavenger
47 capacity against ABTS cation and DPPH stable radicals, and the reducing power. The registered
48 high anti-AGEs capacity could probably be ascribed to dittany polyphenolic composition
49 particularly rich in flavone derivatives. These findings support further investigations to study the
50 feasibility of dittany as antiglycative agents in food or cosmetic preparation.

51

52

53 **Keywords:** glycation inhibitors; carbonyl trapping agents; advanced glycation end products

54 (AGEs); Cretan tea; *Origanum dictamnus* L.; RP-HPLC-DAD-ESI/MSⁿ

55 **1. Introduction**

56 *Origanum dictamnus* L. (known as dittany) is an endemic plant of the island of Crete (Greece)
57 belonging to the family of *Lamiaceae*, genus *origanum*.¹ Dittany was considered as “panacea” by
58 the ancient Greeks and it was used in folk medicine for its healing effects.²⁻⁴ Nowadays, it is widely
59 cultivated on the Crete island as its uses as a herbal tea plant, a spice in distilleries, and a condiment
60 contribute to sustain the local economy.⁵ In the last two decades, a certain number of studies
61 describe the biological effects of *O. dictamnus* decoctions, hydro-alcoholic extracts, and essential
62 oils, such as antimicrobial activities against Gram-negative clinical strains, phytopathogenic
63 bacteria, and pathogenic fungi.⁶⁻¹² Antioxidant capacity, cytotoxic activity against human bronchial
64 epidermoid cancer NSCLC-N6 (non-small cell lung cancer) and P388 (murine leukemia) cell lines,
65 and inhibitory effects on HT29 colon and PC3 prostate cancer cells growth have been also ascribed
66 to dittany components.^{9, 13-19}

67 Because of the biological effects, research has also been focused on the characterization of volatile
68 and not volatile dittany components. More than 80 volatile compounds were identified in the
69 essential oils²⁰⁻²⁴ and several polyphenols were characterized in the aqueous extract
70 (hydroxycinnamic acids^{17, 25-28} and catechins¹⁷) and in different polar solvent extracts (phenolic
71 acids^{11,14,16,18,28,29} and flavonoids^{11,14,18, 28}).

72 In the last decade, beverages rich in polyphenols and phenolic acids have been indicated as sources
73 of Advanced End Glycation products (AGEs) inhibitors.^{30,31} AGEs are the final products deriving
74 from the Maillard reaction or non-enzymatic glycation process that starts with the interaction
75 between the carbonyl group of reducing sugars and the free amino group of proteins, lipids, and
76 nucleic acids, when Amadori rearrangement compounds react with amino groups by either
77 oxidative or non-oxidative pathways.³² Maillard reaction takes place not only in food during
78 processing and storage, but also in living bodies, giving origin to AGEs accumulation *in vivo* and
79 by consequence to the development of age-related disorders.^{33,34} Therefore, the search for new

80 AGE-inhibitors, especially from natural rather than synthetic sources, is considered of particular
81 interest.

82 The aim of the present research is to extend the knowledge of the functional properties of dittany
83 infusion. The main objectives were to study the chemical composition of the beverage by RP-
84 HPLC-DAD-ESI-MSⁿ and to evaluate its anti-glycation effect monitoring different reaction stages
85 and products. For this purpose, different *in vitro* models were studied: (i) inhibition of fructosamine
86 formation (early stage of non-enzymatic protein glycation); (ii) inhibition of the α -dicarbonyl
87 compounds formation (generated after oxidation and dehydration steps in the Maillard reaction);
88 (iii) inhibition of BSA-MGO system (middle stage of non-enzymatic protein glycation) and of
89 BSA-sugar systems (last phase of non-enzymatic protein glycation). Furthermore, the ability of
90 infusion to directly trap MGO and glyoxal (GO) (important intermediates of Maillard reaction) was
91 assessed. A potential relationship of antioxidant activity with AGE-inhibitory effect was also
92 evaluated.

93

94 **2. Materials and methods**

95 **2.1. Chemicals**

96 Ethanol, methanol, D(+) glucose (GLC), D(-) fructose (FRU), disodium hydrogen phosphate
97 dodecahydrate, sodium carbonate decahydrate, sodium bicarbonate were purchased from Carlo Erba
98 (Milano, Italy). 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox C), HPLC-grade
99 and HPLC-MS-grade formic acid, methanol, 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2'-azino-
100 bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (ABTS), nitrotetrazolium blue
101 chloride (NBT), methylglyoxal (MGO, 40% aqueous solution), glyoxal (GO, 40% aqueous
102 solution), 5-methylquinoxaline (5-MQ), *o*-phenyldiamine (grade purity \geq 98%, OPD), bovine
103 serum albumin (grade purity \geq 98%, BSA), D(-)- ribose (grade purity \geq 98%, RIB), aminoguanidine
104 hydrochloride (grade purity \geq 98%, AG), sodium dihydrogen phosphate monohydrate, potassium
105 dihydrogen phosphate, sodium hydroxide pellets, sodium azide (grade purity 99.5%), (-)-

106 gallicocatechin (grade purity \geq 98%), rosmarinic acid (grade purity \geq 98%), apigenin-7-*O*-
107 glucuronide (grade purity \geq 95%), and luteolin-7-*O*-rutinoside (grade purity \geq 95%) were provided
108 by Sigma-Aldrich (St. Louis, Mo, USA). Water was obtained from a Millipore Direct-QTM system
109 (Merck-Millipore, Milan, Italy).

110

111

112 **2.2. Equipment**

113 Vacuum freeze-drier Modulyo System (5Pascal, Italy) was used for freeze-drying process. HPLC-
114 DAD-ESI/MSⁿ analyses were performed using a Thermo Finnigan Surveyor Plus HPLC apparatus
115 (Thermo Fischer Scientific, Waltham, MA, USA) equipped with a quaternary pump, a Surveyor
116 UV-Vis photodiode-array detector, a Surveyor Plus autosampler, and a vacuum degasser connected
117 to a LCQ Advantage Max ion trap spectrometer through an ESI source. Spectrophotometer Perkin-
118 Elmer Lambda25 was used for antioxidant assays. Spectrofluorometer Perkin Elmer L550B was
119 used for antiglycative assays.

120

121 **2.3. Preparation of Cretan tea infusion**

122 Cretan tea (*Origanum dictamnus* L., dittany) dried herb was directly purchased from Anna Herbs,
123 (Heraklion, Crete, Greece). Preparation of Cretan tea infusion was alike in local traditional
124 preparation. Five grams of herb were infused into 200 mL of boiling water (equivalent to a teacup)
125 and the infusion was left to room temperature to cool for 30 min before filtration through filter
126 paper. The beverage was freeze-dried and stored at -20 °C for further assays.

127

128 **2.4. *In vitro* glycation of bovine serum albumin (BSA) induced by monosaccharides (glucose, 129 ribose, fructose) and methylglyoxal and determination of fluorescent Advanced Glycation 130 End-Products (AGEs)**

131 The BSA-GLC, BSA-RIB, BSA-FRU, and BSA-MGO assays were performed according to the
132 methods proposed by Mesías *et al.*³⁵ with slight modifications. Briefly, 35 mg mL⁻¹ BSA was
133 incubated with sugars or MGO (175 mg mL⁻¹ GLC, 150 mg mL⁻¹ RIB, 175 mg mL⁻¹ FRU, and 0.4
134 mg mL⁻¹ MGO) in 100 mM phosphate buffer (pH 7.4) containing 0.02% (w/v) of sodium azide (to
135 ensure aseptic conditions) at 37 °C in absence or presence of dityran solution (or positive control
136 AG) or phosphate buffer (blank). The final reaction mixture contained 500 µL of BSA solution, 1
137 mL of sugar solution, and 375 µL of dityran (5 mg dry matter mL⁻¹ distilled water) or AG (0.5 mg
138 mL⁻¹ 100 mM phosphate buffer, pH 7.4). The systems containing GLC and FRU were incubated
139 for 7 and 14 days, respectively, with four (at 1, 3, 5, and 7 days) and five analytical determinations
140 (at 1, 3, 5, 7, and 14 days), respectively; the system containing RIB was incubated for 1 day
141 monitoring the AGE formation after 1, 3, 6, and 24 h; the system containing BSA-MGO was
142 incubated for 7 days, with analytical determination at 1, 3, and 6 h, and at 1, 5, 7 days. Different
143 incubation and monitoring times are consequence of different sugar and MGO reactivities.³⁶

144 Vesperlysine-like (λ_{exc} 370 nm; λ_{em} 440 nm) AGE fluorescence was measured. Pentosidine-like
145 (λ_{exc} 335 nm; λ_{em} 420 nm) and argpyrimidine-like (λ_{exc} 335 nm; λ_{em} 440 nm) AGE fluorescence
146 were also monitored for the systems containing RIB and MGO, respectively.

147 The percentage inhibition of AGE formation was calculated for each incubation time as follows:

148 Inhibition % = $\{1 - [(\text{Fluorescence of incubation mixture containing sample} - \text{Intrinsic fluorescence}$
149 $\text{of sample}) / \text{Fluorescence of incubation mixture without sample}]\} \times 100$

150 The reported values are the means of three independent experiments, each performed in duplicate.

151

152 **2.5. Evaluation of fructosamine (Amadori products) formation**

153 The Amadori products were measured as fructosamine by nitroblue-tetrazolium (NBT) salt
154 according to the assay described by Zhang *et al.*³⁷ with slight modifications. Glycated material was
155 prepared incubating BSA-GLC, BSA-FRU, and BSA-RIB in presence or absence of dityran
156 solution for 14 days. Glycated BSA (0.5 mL) was mixed with 0.3 mM NBT reagent (2.0 mL) in

157 100 mM bicarbonate-carbonate buffer solutions (pH 10.35) at room temperature for 20 min.
158 Fructosamine present in the systems has the ability to reduce NBT to tetrazinoyl radical forming
159 monoformazano (MF⁺), a coloured compound whose presence can be measured
160 spectrophotometrically at 530 nm.

161 The ability of samples to inhibit the fructosamine formation was calculated as follows:

162 Inhibition % = $\{1 - [(Absorbance\ of\ glycated\ system\ containing\ BSA,\ sugar,\ and\ inhibitor -$
163 $Intrinsic\ absorbance\ of\ system\ containing\ BSA\ and\ inhibitor) / (Absorbance\ of\ glycated\ system$
164 $without\ inhibitor - Absorbance\ of\ BSA)]\} \times 100$

165 The reported values are the means of three independent experiments, each performed in duplicate.

166

167 **2.6. Evaluation of direct MGO and GO-trapping capacity by RP-HPLC-DAD method**

168 Following the method proposed by Mesías *et al.*³⁵ with slight modifications, 100 µL aliquot of 5.2
169 mM GO (in 100 mM phosphate buffer, pH 7.4) or 5.2 mM MGO (in 100 mM phosphate buffer, pH
170 7.4) solutions were added to 50 µL of 5-MQ (internal standard, 6.1 mmol L⁻¹ in water/methanol,
171 50:50, v/v), and to 100 µL of dittany aqueous solution (10 mg dry matter mL⁻¹) or phosphate buffer
172 (control). After the dilution with phosphate buffer to a final volume of 1 mL, the reaction mixture
173 was incubated at 37 °C for 1, 3, 6, 24, 72, and 168 h. After the addition of 200 µL of OPD (10.8 mg
174 mL⁻¹ in phosphate buffer), the mixtures were submitted to a derivatization step at 37 °C for 30 min
175 and the residual GO and MGO were quantified as quinoxaline derivatives by HPLC-DAD. The
176 separations were carried out on a Gemini[®] C18 analytical column (150 × 2.0 mm i.d., 5 µm,
177 Phenomenex, Torrance, CA) with a Hypersil Gold C18 guard column (10 × 2.1 mm i.d., 5 µm,
178 Phenomenex, Torrance, CA) at a constant flow rate of 0.3 mL/min (injection volume 5 µL). The
179 elution was carried out in isocratic mode using as mobile phase a solvent mixture consisting of
180 0.5% acetic acid aqueous solution and methanol, 50/50, v/v. Chromatograms were registered at 315
181 nm. The amount of unreacted GO or MGO was calculated from the ratio of quinoxaline or 2-

182 methylquinoxaline (2-MQ) obtained by the conversion of GO and MGO, respectively, and 5-MQ
183 used as internal standard.

184 The percentage of GO and MGO trapped was calculated as follows:

185
$$\text{GO or MGO decrease (\%)} = \frac{[(\text{Amount of GO or MGO in control sample} - \text{Amount of GO or MGO in sample containing extract}) / \text{Amount of GO or MGO in control sample}] \times 100$$

187 The reported values are the means of three independent experiments, each performed in duplicate.

188

189 **2.7. Spectrophotometric analysis of dicarbonyl compounds**

190 Alpha dicarbonyl compounds were measured spectrophotometrically by Girart-T assay according to
191 the method described by Xu *et al.*³⁸ Briefly, 0.4 mL glycated material was incubated with 0.2 mL
192 Girart-T solution (500 mM) and 3.4 mL sodium formate (500 mM, pH 2.9) at room temperature for
193 1 h. The absorbance was registered at 294 nm against blank containing all reagents except Gerart-T
194 solution. The content of dicarbonyl compounds was calculated as glyoxal equivalent after the
195 construction of a calibration curve in the concentration range of 0.5 - 40 μM for the system
196 containing GLC and of 40 - 250 μM for the systems containing FRU and RIB.

197

198 **2.8. DPPH assay**

199 Antiradical activity was evaluated as scavenging activity against the stable coloured DPPH free
200 radical.³⁹ Briefly, a 100 μL aliquot of sample solutions (40 mg dry matter mL^{-1}) or $\text{KH}_2\text{PO}_4/\text{NaOH}$
201 buffer, pH 7.4, (control) was added to 3.9 mL of a $6 \times 10^5 \text{ mol L}^{-1}$ methanol/ $\text{KH}_2\text{PO}_4/\text{NaOH}$ buffer
202 (50:50 v/v) DPPH radical solution. The mixture discoloration was monitored at 515 nm after 20
203 min of reaction. The antiradical activity was calculated as follows:

204
$$\text{Anti-DPPH activity (\%)} = \frac{[(\text{Absorbance of control} - \text{Absorbance of sample}) / \text{Absorbance of control}] \times 100$$

205

206 Methanolic solutions of Trolox C in the concentration range of 15-300 $\mu\text{mol L}^{-1}$ were used for
207 calibration. Results were expressed as $\mu\text{mol Trolox equivalent antioxidant capacity (TEAC) g}^{-1}$ dry
208 sample. LOQ was 2.4 $\mu\text{mol TEAC g}^{-1}$ dry sample.

209 The reported values are the means of three independent experiments, each performed in duplicate.

210

211 **2.9. ABTS assay**

212 Scavenging activity against ABTS cation (ABTS^{++}) was evaluated as described by Delgado-
213 Andrade *et al.*⁴⁰ with slight modifications. ABTS stock solution was prepared by reacting 7 mM
214 cation radical with 2.45 mM potassium persulfate and allowing the reaction mixture to stand in the
215 dark at room temperature for 16 h before use. Then the mixture was diluted with distilled water
216 (absorbance value of 0.70 ± 0.02 at 734 nm). A 40 μL aliquot of dittany aqueous solution (50 mg
217 dry matter mL^{-1}) or water (control) was added to 500 μL of diluted ABTS^{++} solution and to 1460 μL
218 of water. The absorbance of the reaction mixture was taken at 734 nm after 10 min. The ability to
219 scavenge ABTS^{++} was calculated as follows:

220 ABTS^{++} scavenging activity (%) = $[(\text{Absorbance of control} - \text{Absorbance of sample}) / \text{Absorbance}$
221 $\text{of control}] \times 100$

222 Methanolic solutions of Trolox C in the concentration range of 0.05-50 $\mu\text{mol L}^{-1}$ were used for
223 calibration. Results were expressed as $\mu\text{mol Trolox equivalent antioxidant capacity (TEAC) g}^{-1}$ dry
224 sample. LOQ was 0.03 $\mu\text{mol TEAC g}^{-1}$ dry sample.

225 The reported values are the means of three independent experiments, each performed in duplicate.

226

227 **2.10. Reducing power assay**

228 The reducing power was determined as previously described by Natic *et al.*⁴¹ with slight
229 modifications. A 1 mL aliquot of infusion (2.55 mg dry material mL^{-1}) was mixed in a test tube
230 with 0.4 mL of potassium hexacyanoferrate (III) (0.02 M), 0.05 mL of chloridric acid (0.01 M), 0.4

231 mL of iron(III) chloride (0.02 M), and 0.7 mL of distilled water. The absorbance of the reaction
232 mixture was taken at 720 nm after 15 min of incubation in the dark. Methanolic solutions of Trolox
233 C in the concentration range of 10-200 $\mu\text{mol L}^{-1}$ were used for calibration. Reducing substances
234 were expressed as $\mu\text{mol Trolox equivalent antioxidant capacity (TEAC) g}^{-1}$ dry sample.

235 The reported values are the means of three independent experiments, each performed in duplicate.

236

237 **2.11. RP-HPLC-DAD-ESI/MSⁿ analysis**

238 HPLC-DAD-ESI/MSⁿ analysis were carried out on an Ascentis[®] Express C18 analytical column
239 (150 x 2.0 mm i.d., 2.7 μm , Supelco[®], Bellefonte, PA) at a constant flow rate of 0.3 mL min⁻¹
240 (injection volume 20 μL). The mobile phase consisted of A (0.1% formic acid in water), and B
241 (methanol) with the following gradient table: 0-10 min, 5-8% B; 10-60 min, 8-40% B; 60-70 min,
242 40-60% B; 70-80 min, 60-100% B; 80-90 min, 100% B, followed by column reconditioning in 10
243 min. Chromatograms were recorded at 254 nm (flavones), 280 nm (phenolic acids), 314 nm
244 (hydroxycinnamic acids), and 370 nm (flavonols). The ion trap operated in data-dependent, full
245 scan (60-1500 m/z), and MSⁿ mode to obtain fragment ion m/z with a 35% and an isolation width of
246 3 m/z . The mass spectrometric parameters were set by flow injection analysis of gallic acid and
247 apigenin-7-*O*-glucuronide (10ppm in 0.1% formic acid –ACN solution, 50:50, v/v) as below:
248 ionization polarity, negative and positive; sheat gas glow rate, 50 arbitrary units (AU); auxiliary gas
249 flow rate, 20 AU; ionization voltage, 5 kV; capillary temperature, 400 °C. The Thermo Fischer
250 Scientific Excalibur 2.1 software was used for data acquisition and processing.

251

252 **2.12. Statistical Analysis**

253 Data from at least three replicated experiments performed in duplicate were expressed as mean \pm
254 standard deviations (SD) of measurements. Differences were considered to be significant at $P <$
255 0.05 and $P < 0.01$. All statistical analysis was carried out using Microsoft Excel 2010.

256

257 3. Results and Discussion

258 3.1 Chemical characterization of infusion by RP-HPLC-DAD-ESI-MSⁿ

259 The qualitative profile of the infusion was performed using RP-HPLC-DAD-ESI-MSⁿ using data-
260 dependent acquisition that combines the putative molecular mass (MM) obtained by single stage
261 MS with UV detection and tandem MS analysis acquired by applying user-specified criteria to
262 select the ion of interest for subsequent fragmentation. Additional targeted MSⁿ experiments have
263 been performed on selected pseudomolecular ions for structure confirmation, if necessary.

264 Among the eight flavones detected in the infusion, compound 3 was a C-glycoside (Figure 1). This
265 was putatively identified as 6,8-di-C-hexosyl-apigenin, a di-C-glycosylated flavone, by comparing
266 its fragmentation pattern with that reported in literature.^{42,43} It showed a molecular ion at m/z 593 in
267 negative ionization mode. The fragmentation pattern consisted in the subsequent losses of 120 Da
268 giving the peak base at m/z 473 and the secondary ion at m/z 353, respectively. The loss of 120 Da
269 is characteristic of the presence of a hexosidic residue bound to aglycone through a C-C bond. The
270 fragment at 353 m/z corresponds to the aglycone apigenin +113 Da and it is an ion that could be
271 easily observed for C-glycosil flavones. Glucuronide derivatives of apigenin were also detected. In
272 particular, apigenin-7-*O*-glucuronide was identified (compound 13); its structure was also
273 confirmed by comparing its selectivity and fragmentation pattern with those obtained for the
274 standard compound analysed in the same conditions. The molecular ion at m/z 445 produced an ion
275 at m/z 269 corresponding to apigenin by the neutral loss of glucuronic acid (176 Da). Compound 9
276 showed a molecular ion at m/z 621 which fragmented producing a base peak at m/z 351 due to the
277 loss of the aglycon and a secondary peak at m/z 269 corresponding to apigenin aglycon and due to
278 the loss of two glucuronide residues [M-H-(176 x 2)]⁻. The molecular structure hypothesized was
279 apigenin-7-*O*-diglucuronide. Two isobaric derivatives of apigenin with molecular ion at m/z 797
280 (compounds 5 and 8) were putatively identified as apigenin-*O*-triglucuronide. In both cases a base
281 peak at m/z 527 [M-H-aglycon]⁻ and a low abundance signal corresponding to aglycone ion at m/z
282 269 [M-527]⁻ were registered in MS/MS spectra. Furthermore an ion at m/z 351 due to the loss of

283 apigenin-monoglucuronide residue was also detected.⁴⁴⁻⁴⁶ Glucuronide derivatives of apigenin were
284 previously identified in aromatic species of *Origanum majorana*⁴⁶, but never before in *O.*
285 *dictamnus*.

286 Two luteolin derivatives (compounds 6 and 14) were also found in dittany infusion. The first
287 compound was putatively identified as luteolin-7-*O*-diglucuronide (6). MS² experiments produced
288 ions at m/z 351 (base peak) and m/z 285 from the fragmentation of the molecular ion at m/z 637 [M-
289 H]⁻.^{47,48} The second luteolin derivative had the same molecular mass of 6,8-di-*C*-hexosyl-apigenin
290 (594 Da), but the fragmentation pattern was different. In fact, a base peak at m/z 285 corresponding
291 to luteolin aglycone, which is generated by the loss of a rutinose residue [M-H-308]⁻ and a radical
292 ion at m/z 286 with low abundance were registered. Considering that the ratio between the
293 intensities of aglycone and radical aglycone ions are closely correlated to the glycosylation position,
294 the compound was identified as luteolin-7-*O*-rutinoside (14).⁴⁶ The structure was also confirmed by
295 the analysis of pure standard. The last flavone derivative detected was 5,4'-dihydroxy-6,7,8-
296 trimethoxyflavone (xantomicol) (16). Its MS and MS/MS spectra registered in positive ionization
297 mode showed a molecular ion at m/z 345 which fragmented giving a base peak at m/z 330 (loss of
298 15 Da [M+H-15]⁺) and ions at m/z 315 (50%) and 313 (45%). Its molecular structure was
299 tentatively identified by comparing the obtained fragmentation with that reported in literature for
300 the same compound identified in different *Origanum* species.⁴⁹

301 Considering flavonols, two kaempferol derivatives were detected in dittany infusion (compounds 7
302 and 15). They showed a molecular ion at m/z 813 [M-H]⁻ which fragmented in three glucuronic acid
303 residues [176 Da x 3]⁻ generating a base peak at m/z 527 by the loss of kaempferol, and secondary
304 ions at m/z 351 and 285 following the loss of kaempferol monoglucuronide and three glucuronic
305 acid residues, respectively. The isobaric compounds were tentatively identified as kaempferol-7-*O*-
306 triglucuronide and kaempferol-3-*O*-triglucuronide.⁴⁴

307 Compound 4 was identified as galocatechin due to its molecular mass of 306 Da (m/z 305, [M-H]⁻)
308 and its fragmentation pattern which showed a base peak at m/z 225. This structure was also

309 confirmed by the analysis of standard compound. This compound was previously identified in other
310 Lamiaceae species and in particular in *O. majorana*.^{46,50}

311 The analysis of the MS spectrum of *O. dictamnus* infusion revealed the presence of six
312 hydroxycinnamic acid derivatives, among which five different isoforms of salvianolic acid.
313 Compound 10 at m/z 359 was characterized as rosmarinic acid. The MS/MS spectrum of this
314 compound provided fragment ions at m/z 161 (base peak) [caffeic acid-H- 2H₂O]⁻ by losing two
315 molecules of water, and m/z 197 and 179 corresponding to 2-hydroxy derivative of hydrocaffeic
316 acid and caffeic acid, respectively⁴⁶. The presence of this acid in dittany and other vegetables
317 belonging to Lamiaceae family was already reported in literature.⁵¹⁻⁵³ Regarding salvianolic acid
318 derivatives, compound 12 was putatively identified as salvianolic acid K by comparing the
319 fragmentation pattern with literature data.^{43,54} It showed [M-H]⁻ ion at m/z 555 which was subjected
320 to a decarboxylation and a dehydration, giving a base peak at m/z 493 and a secondary peak at m/z
321 359, which has a relative abundance of about 20% corresponding to rosmarinic acid after the loss of
322 3,4-dihydroxyvinilbenzenic moiety.⁴³ This compound was previously described in a methanolic
323 extract of *O. dictamnus*⁵⁵ and also in *Thymus longicaulis*.⁴³ Compound 17 was putatively identified
324 as salvianolic acid B (molecular ion at m/z 717), known to be present in *O. majorana*⁴⁶; its
325 fragmentation pattern consisted of a base peak at m/z 519 following the loss of 3-(3,4-
326 hydroxyphenyl)lactic acid (danshensu) moiety [M-H-198]⁻, an ion with very low intensity at m/z
327 475 [M-danshensu-CO₂-H]⁻, an ion deriving from the loss of the second danshensu moiety at m/z
328 321 [M-H-198-198], and an ion at m/z 339 [M-danshensu-caffeic acid-H]⁻.^{43, 56,57} An isobaric
329 compound was detected in our infusion and the hypothetical structure could be isosalvianolic acid B
330 (20) due to the lack in its MS/MS spectrum of the ion at m/z 321, as previously reported by
331 Taamalli.⁴⁶ Compound 18 was putatively identified as salvianolic acid I through MS² and MS³
332 experiments. In fact, it showed a molecular ion at m/z 537 which fragmented to m/z 493 [M-H-
333 CO₂]⁻, to m/z 339 [M-H-198]⁻ corresponding to danshensu moiety, and to m/z 313 [M-H-CO₂-180]⁻.
334 The molecular structure was confirmed by MS³ experiments which led to the generation of an ion at

335 m/z 179 corresponding to caffeic acid. The presence of salvianolic acid I was not surprising because
336 several researches underlined the presence of salvianolic acids in different types of sage, which
337 belongs to the same family of dittany.⁴⁶ Another compound with MM 538 Da was detected
338 (compound 11). It was putatively identified as lithospermic acid by its fragmentation pattern very
339 similar to that of salvianolic acid I, but lacking of the fragment at m/z 339. The presence of this acid
340 was previously reported in *O. vulgare* by Martins *et al.*⁵⁸ and in *O. majorana* by Taamalli *et al.*⁴⁶
341 The last salvianolic acid derivative detected was a compound with a molecular mass of 494 Da (19)
342 putatively identified as salvianolic acid A.^{59,60} In negative ionization mode its fragmentation
343 produced a base peak at m/z 295 by the loss of danshesu moiety, an intense secondary peak at m/z
344 185 $[M-H-C_6H_6O_2]^-$ and a low abundant ion at m/z 109 $[C_6H_6O_2-H]^-$. This compound here
345 tentatively identified was never before detected in *Origanum* species.

346 A *p*-hydroxyphenylpropionic acid-O-hexoside (compound 1) was tentatively identified by its MS
347 and MS/MS spectra. The molecular ion registered in negative ionization mode was at m/z 327, and
348 it is also present in the spectrum as formiate derivative. It fragmented to m/z 165 following the loss
349 of an hexose moiety $[M-H-162]^-$ and to a low abundant ion at m/z 121 due to the loss of carboxylic
350 group from m/z 165. Compound 2 showed a molecular mass of 388 Da. Its fragmentation pattern
351 consisted of a base peak at m/z 207 and secondary peaks at m/z 163 (due to the decarboxylation of
352 the base peak), and at m/z 369. The further fragmentation of the ion at m/z 207 gave an ion at m/z
353 163. Comparing these data with the literature ones, the compound could be 12-hydroxyjasmonic-*O*-
354 hexoside acid, before detected in the aerial part of a Greek *O. vulgare*.^{61,62}

355 In conclusion, we identified twenty compounds in dittany infusion, among which nine flavones, two
356 flavonols, one catechin, and seven phenolic acids (Table 2). Only rosmarinic acid and salvianolic
357 acid B were previously identified in Cretan dittany.

358

359 **3.2. Antiglycative capacity of the infusion**

360 An herbal tea daily consumed by Greeks was investigated as a promising functional beverage useful
361 in the reduction of non-enzymatic protein glycation and in the scavenging free radicals.

362 Firstly, the effect on the early stage of non-enzymatic glycation of protein was monitored by the
363 inhibition of fructosamine formation. Fructosamine is an Amadori product generated by the
364 rearrangement of Schiff's bases that originates from the reaction between the carbonyl groups of
365 monosaccharides with the amino groups of proteins after condensations, rearrangements, and
366 oxidative modifications.⁶³ Considering that different rates of protein glycation could be registered
367 depending on the sugar, the formation of fructosamine was investigated under mild reaction
368 conditions applied in *in vitro* system containing three different dietary monosaccharides (GLC,
369 FRU, and RIB) by NBT assay. Amadori products formed after 14 days of incubation were
370 spectrophotometrically monitored by the reduction of NBT yielding to a coloured compound. The
371 reduction of NBT was inhibited by incubating dittany infusion with all the sugars-BSA systems
372 used. The inhibitory percentage were 14.38 ± 0.05 , 41.96 ± 1.77 , and 9.17 ± 0.25 for GLC, FRU,
373 and RIB, respectively. The values registered for FRU-glycation system were significantly higher
374 than those registered for the other two monosaccharides ($P < 0.01$).

375 After oxidation and dehydration steps in the Maillard reaction, dicarbonyl compounds, considered
376 as AGEs precursors, were generated. The inhibitory effect of the infusion on the α -dicarbonyl
377 compounds formation was calculated using a standard curve for GO. As shown in Figure 2, both
378 dittany infusion and AG, used as positive control, inhibited the formation of dicarbonyl compounds
379 generated at different concentration levels depending on the sugar present in the glycated material.
380 In fact, dittany showed a significantly stronger inhibitory effect than AG in the systems containing
381 GLC and FRU starting from 2 and 1 day, respectively. Conversely, when RIB is present in the
382 system dittany showed higher efficacy than AG which had no activity for a period shorter than 4
383 days.

384 As MGO can react with serum albumin acting as intermediary for AGEs formation, the system
385 BSA-MGO could be useful to evaluate the middle stage of protein glycation, while the systems

386 BSA-sugar could be useful to evaluate the last phase of non-enzymatic glycation process.
387 Therefore, the ability of dittany infusion to inhibit AGEs formation promoted by the three above
388 mentioned sugars and MGO were monitored. In particular, the formation of fluorescent AGEs were
389 monitored. Different time monitoring were selected for each system according to the different
390 reactivity of the sugar considered and of MGO; in fact, the fluorescence intensity of the glycated
391 material significantly increased throughout the incubation period, but dramatically decreased after
392 14 days when GLC is present in the system, after 7 days in presence of FRU or MGO, and after 1
393 day with RIB. These kinetics are in accordance with those obtained by Sadowska-Bartosz *et al.*⁶⁴
394 indicating RIB as the most reactive sugar, followed by FRU and GLC. In previous investigations,
395 the highest RIB reactivity was explained by its planar structure eliciting the unstable aldofuranose
396 ring to easily react with the amino groups.⁴³ Preliminary studies on the relationship between
397 infusion concentration and activity were performed using final concentrations in reaction medium
398 ranging from 20 μg to 1 mg mL^{-1} . One mg mL^{-1} was the concentration able to generate the highest
399 inhibitory activity in all the systems (data not shown) and therefore all tests were performed
400 incubating this concentration. AG was always used as positive control due to its well-known action
401 in the glycation process. Figure 3 shows the effect of the infusion on fluorescent AGEs formation in
402 BSA-GLC system. The inhibitory capacity at the beginning of the monitoring period was about 72
403 % and it was significantly lower than the activity of the positive control AG. Then, the effect of the
404 infusion increased with the reaction time, differently from that of AG showing a particular kinetic in
405 the inhibition of AGE formation, as evident in the decreased inhibition value registered for a longer
406 time; in fact, after 14 days of incubation dittany was able to inhibit almost completely vesperlysine-
407 like AGEs generated in the system. Differently, the high activity values registered after 1 day of
408 incubation in the system containing FRU were close to those registered for AG (> 90%) and then
409 increased till 5 days when dittany completely inhibited AGEs formation; at the end of the
410 monitoring period (7 days) the activity decreased reaching 90% of inhibitory capacity (Figure 4).

411 In the BSA-RIB system (Figure 5), the activity registered in the inhibition of vesperlysine-like and
412 pentosidine-like AGEs was very similar during the entire monitoring time with values ranging from
413 about 84 to 96%, and always significantly higher ($P<0.01$) than the activity registered for AG at the
414 same times. After 24 h a slight but significant ($P<0.05$) reduction in the capacity of inhibiting the
415 formation of both types of AGEs in respect to the values registered at 1h was recorded. The kinetic
416 profiles registered for vesperlysine-like and pentosidine-like AGEs seemed to be less affected by
417 the chemical structures of the compounds present in dittany infusion in comparison to other
418 extracts, as previously reported in literature. In fact, extracts particularly rich in hydroxycinnamic
419 acid derivatives, showed a different activity profile according to the different type of AGEs
420 generated probably because of molecular structural changes under simil-physiological conditions as
421 in the systems here studied.^{65, 66}

422 As regards the action of the infusion in the system consisting of BSA and MGO, the capacity of the
423 tested extract to inhibit vesperlysine-like and argpyrimidine-like AGEs was demonstrated (Figure
424 6). In particular, considering the inhibition of the formation of versperlysine-like AGEs, dittany
425 showed activity values significantly higher ($P<0.01$) than those registered for AG at all the
426 monitoring times; it was able to totally counteract AGEs formation after 1 h, decreasing its activity
427 progressively till 1 day when a value of 82% was reached, and then increasing its activity till 7
428 days. Conversely, similar very high activity values close to 100% were registered both for dittany
429 and AG when considering argpyrimidine-like AGEs formation after 1 and 3 h of incubation.
430 Increasing the incubation time, only a slight decrease in the inhibitory capacity was registered for
431 dittany, differently from AG which showed statistically significant ($P<0.01$) reduction.

432 Considering that GO and MGO are important precursors in the formation of AGEs due to their
433 comparatively higher reactivity than reducing sugars to attack amino groups in proteins, trapping
434 these carbonyl should be an effective strategy to alleviate the carbonyl stress. Therefore, the
435 capacity to directly trap GO and MGO was also evaluated. In Figure 7 the ability of dittany infusion
436 to act as trapping-agent is recorded at different times starting from 1 h up to 7 days (168 h). The

437 results showed that the trapping capacity of MGO is generally higher than that of GO in the first 24
438 h of monitoring; conversely, for longer time both of them were completely trapped.

439 Considering that the second period of the glycation reaction was characterized by the free-radical
440 mediated conversion of the Amadori products to AGEs, in order to verify if the antiglycative effect
441 registered for the infusion may be associated with its antioxidant/antiradical activity, three different
442 assays, i.e. ABTS cation radical scavenging activity test, DPPH free radical scavenging capacity
443 method, and reducing capacity assay were used. In Table 1 the obtained results are reported. Dittany
444 showed a high capacity in reducing oxidative substances and in acting as anti-DPPH radical.
445 Conversely, only a weak ABTS cation radical scavenging capacity was registered. Therefore, a
446 correspondence between DPPH or reducing power and antiglycative capacity was found in all the
447 methods used.

448 Several studies previously pointed out the antioxidant and antiglycation capacities of herbal
449 infusions, such as black and green tea (*Camellia sinensis*), balm (*Melissa officinalis*), sage (*Salvia*
450 *officinalis*), common verbena (*Verbena officinalis*), some Thai herbal teas, and mate tea (*Ilex*
451 *paraguariensis*).^{67,68} The inhibitory effects on AGEs registered for dittany infusion are similar with
452 those reported in particular for black and green tea in BSA-GLC and BSA-MGO systems by Ho *et*
453 *al.*⁶⁷ and for Guava tea in BSA-GLC⁶⁹, and the activity values are higher than those registered for
454 sage, common verbena and lemon grass (*Cymbopogon citratus*) herbal tea.^{67,68} Moreover, the
455 antiglycative activity of dittany is higher than that of mate tea in BSA-MGO system⁷⁰ and than that
456 of mate tea and coffee in BSA-FRU system.⁷¹ The antiglycative activity is generally correlated to
457 the polyphenolic composition of the extracts. In particular, previous structure-activity studies
458 indicated that flavones are able to exhibit stronger inhibitory effects when compared to flavonols,
459 flavanones, and isoflavones.⁷² The composition of dittany infusion rich in apigenin, luteolin,
460 kaempferol, and also hydroxycinnamic acid derivatives could justify the high antiglycative activity
461 registered.

462

463 **4. Conclusion**

464 This study illustrated that dittany infusion was a complex mixture consisting of several flavones,
465 flavonols, and hydroxycinnamic acid derivatives. Cretan tea was proved to have inhibitory effects
466 on AGEs formation being very active as antiglycative agent in the incubation systems consisting of
467 a model protein and different sugars or MGO. This effect may be partially related with its
468 antioxidant/antiradical activity and could be ascribed to its composition in flavones, flavonols, and
469 hydroxycinnamic acid derivatives.

470 As the capacity of inhibiting the formation of dicarbonyl compounds and AGEs was stronger than
471 that of reducing Amadori products, we could indicated that the antiglycative action of the tested
472 beverage occurred primarily during the last two phases of the non-enzymatic glycation reaction.

473 These findings are relevant for enhancing the functional properties of Cretan tea beverage even if
474 more investigations are highly recommended to evaluate the potentially use of such beverage as
475 food supplement useful as inhibitor of the non-enzymatic glycation process, involved in chronic and
476 degenerative disorders. To this purpose, the protective effects of the infusion will be tested with
477 novel *in vitro* approaches based on the use of dynamic bioreactors, which are more similar to
478 physiological compartments *in vivo*.

479

480 **Conflicts of interest**

481 There are no conflicts of interest to declare.

482 **Acknowledgements**

483 This research was supported by Merck KGaA for consumable materials.

484 **5. References**

- 485 1 A. Strid and K. Tan, *Mountain flora of Greece vol. 2*, Edinburgh University Press, Edinburgh,
486 1991.
- 487 2 D. Vokou, K. Katradi and S. Kokkini, Ethnobotanical survey of Zagori (Epirus, Greece), a
488 renowned centre of folk medicine in the past, *J. Ethnopharmacol.*, 1993, 39, 188-196.
- 489 3 H. Baumann, *Greek wild flowers and plant lore in ancient Greece*, The Herbert Press Ltd.,
490 London, 1996, p. 119-121.
- 491 4 C. C. Liolios, K. Graikou, E. Skaltsa and I. Chinou, Dittany of Crete: a botanical and
492 ethnopharmacological review, *J. Ethnopharmacol.*, 2010, 131, 229-241.
- 493 5 E. Hanlidou, R. Karouspu, V. Kleftoyanni and S. Kokkini, The herbal market of Thessaloniki (N-
494 Greece) and its relation to the ethnobotanical tradition, *J. Ethnopharmacol.*, 2004, 91, 281-299.
- 495 6 M. S. Karanika, M. Komaitis and G. Aggelis, Effect of aqueous extracts of some plants of
496 Lamiaceae family on the growth of *Yarrowiali polytica*, *Int. J. Food Microbiol.*, 2001, 64, 175-
497 181.
- 498 7 N. Choriantopoulos, E. Kalpoutzakis, N. Aligiannis, S. Mitaku, G. J. Nychas and S. A.
499 Haroutounian, Essential oils of *Satureja*, *Origanum*, and *Thymus* species: chemical composition
500 and antibacterial activities against food borne pathogens, *J. Agric. Food Chem.*, 2004, 52, 8261-
501 8267.
- 502 8 N. Fokialakis, E. Kalpoutzakis, B. L. Tekwani, S. I. Khan, M. Kobaisy, A. L. Skaltsounis and S.
503 O. Duke, Evaluation of the animalarial and antileishmanial activity of plants from the Greek
504 island of Crete, *J. Nat. Med.*, 2007, 61, 38-45.
- 505 9 O. Gortzi, S. Lalas, L. Chinou and J. Tsaknis, Evaluation of the antimicrobial and antioxidant
506 activities of *Origanum dictamnus* extracts before and after encapsulation in liposomes,
507 *Molecules*, 2007, 12, 932-945.

- 508 10 C. C. Liolios, O. Gortzi, S. Lalas, J. Tsaknis and I. Chinou, Liposomal incorporation of carvacrol
509 and thymol isolated from the essential oil of *Origanum dictamnus* L. and *in vitro* antimicrobial
510 activity, *Food Chem.*, 2009, 112, 77-83.
- 511 11 A. Chatzopoulou, A. Karioti, C. Gousiadou, V. L. Vivancos, P. Kyriazopoulos, S. Golegou and
512 H. Skaltsa, Depsides and other polar constituents from *Origanum dicatamnus* L. and their *in*
513 *vitro* antimicrobial activity in clinical strains, *J. Agric. Food Chem.*, 2010, 58, 6064-6068.
- 514 12 C. Lionis, Evidence-based innovative therapeutic medicine of Cretan plants: some encouraging
515 specific functions and claims, *Hell. J. Nucl. Med.*, 2015, 18, S1:145.
- 516 13 M. Couladis, O. Tzakou, E. Verykokidou and C. Harvala, Screening of some Greek aromatic
517 plants for antioxidant activity, *Phytother. Res.*, 2003, 17, 194-195.
- 518 14 G. Kouri, D.Tsimogiannis, H. Bardouki and V. Oreopoulou, Extraction and analysis of
519 antioxidant components from *Origanum dictamnus*, *Innov. Food Sci. Emerg. Technol.*, 2007, 8,
520 155-162.
- 521 15 V. Lagouri, A. Bantouna and P. Stathopoulos, A comparison of the antioxidant activity and
522 phenolic content of nonpolar and polar extracts obtained from four endemic lamiaceae species
523 grown in Greece, *J. Food Process. Preserv.*, 2010, 34, 872-886.
- 524 16 V. Exarchou, P. G. Takis, M. Malouta, J. Vervoort, E. Karali and A. N. Troganis, Four new
525 depsides in *Origanum dicatmnus* methanol extract, *Phytochem. Lett.*, 2013, 6, 46-52.
- 526 17 A. C. Kaliora, D. A. A. Kogiannou, P. Kefalas, I. S. Papassideri and N. Kalogeropoulos,
527 Phenolic profiles and antioxidant and anticarcinogenic activities of Greek herbal infusions;
528 balancing delight and chemoprevention?, *Food Chem.*, 2014, 142, 233-241.
- 529 18 C. Proestos, K. Lytoudi, O. K. Mavromelanidou, P. Zoumpoulakis and V. J. Sinanoglou,
530 Antioxidant capacity of selected plant extracts and their essential oils, *Antioxidants*, 2013, 2,
531 11-22.
- 532 19 I. Chinou, C. Liolios, D. Moreau and C. Roussakis, Cytotoxic activity of *Origanum dictamnus*,
533 *Fitoterapia*, 2007, 78, 342-344.

- 534 20 C. Economakis, C. Demetzos, T. Anastassaki, V. Papazoglou, M. Gazouli, A. Loukis, C. A.
535 Thanos and C. Harvala, Volatile constituents of bracts and leaves of wild and cultivated
536 *Origanum dictamnus*, *Planta Med.*, 1999, 65, 189-191.
- 537 21 N. G. Ntalli, F. Ferrari, I. Giannakou and U. Menkissoglu-Spiroudi, Phytochemistry and
538 nematicidal activity of the essential oils from 8 Greek Lamiaceae aromatic plants and 13
539 terpenes components, *J. Agric. Food Chem.*, 2010, 58, 7856-7863.
- 540 22 G. Mitropoulou, E. Fitsiou, E. Stavropoulou, E. Papavassilopoulou, M. Vamvakias, A. Pappa, A.
541 Oreopoulou and Y. Kourkoutas, Composition, antimicrobial, antioxidant, and antiproliferative
542 activity of *Origanum dictamnus* (dittany) essential oil, *Microb. Ecol. Health Dis.*, 2015, 26:
543 26543.
- 544 23 M. Marrelli, F. Conforti, C. Formisano, D. Rigano, N. A. Arnold, F. Menichini and F. Senatore,
545 Composition, antibacterial, antioxidant and antiproliferative activities of essential oils from
546 three *Origanum* species growing wild in Lebanon and Greece, *Nat. Prod. Res.*, 2016, 60, 735-
547 739.
- 548 24 C. Proestos, D. Sereli and M. Komaitis, Determination of phenolic compounds in aromatic
549 plants by RP-HPLC and GC-MS, *Food Chem.*, 2006, 95, 44-52.
- 550 25 A. K. Atoui, A. Mansouri, G. Boskou and P. Kefalas, Tea and herbal infusions: their antioxidant
551 activity and phenolic profile, *Food Chem.*, 2005, 89, 27-36.
- 552 26 C. Proestos, M. Kapsokefalou and M. Komaitis, Analysis of naturally occurring phenolic
553 compounds in aromatic plant by RP-HPLC and GC-MS after silylation, *J. Food Qual.*, 2008,
554 31, 402-414.
- 555 27 V. Lagouri and G. Alexandri, Antioxidant properties of Greek *O. dictamnus* and *R. officinalis*
556 methanol and aqueous extracts – HPLC determination of phenolic acids, *Int. J. Food Prop.*,
557 2013, 16, 549-562.
- 558 28 Y. C. Fiamegos, C. G. Nanos, J. Vervoort and C. D. Stalikas, Analytical procedure for the in-vial
559 derivatization-extraction of phenolic acids and flavonoids in methanolic and aqueous plant

- 560 extracts followed by gas chromatography with mass-selective detection, *J. Chromatogr. A.*,
561 2004, 1041, 11-18.
- 562 29 C. Proestos and M. Komaitis, Analysis of naturally occurring phenolic compounds in aromatic
563 plants by RP-HPLC coupled to diode array detector (DAD) and GC-MS after silylation, *Foods*,
564 2013, 2, 90-99.
- 565 30 E. Verzelloni, D. Tagliazucchi, D. Del Rio, L. Calani and A. Conte, Antiglycative and
566 antioxidative properties of coffee fractions, *Food Chem.*, 2011, 124, 1430-1435.
- 567 31 A. Gugliucci, D. H. Markowicz Bastos, J. Schulze and M. Ferreira Souza, Caffeic and
568 chlorogenic acids in *Ilex paraguariensis* extracts are the main inhibitors of AGE generation by
569 methylglyoxal in model proteins, *Fitoterapia*, 2009, 80, 339-344.
- 570 32 R. Singh, A. Barden, T. Mori and L. Beilin, Advanced glycation end-products: a review,
571 *Diabetologia*, 2001, 44, 129-146.
- 572 33 K. Nowotny, T. Jung, A. Hohn, D. Weber and T. Gune, Advanced glycation end products and
573 oxidative stress in type 2 diabetes mellitus, *Biomolecules*, 2015, 5, 194-222.
- 574 34 J. W. Baynes, The role of AGEs in aging: causation or correlation, *Exp. Gerontol.*, 2001, 36,
575 1527-1537.
- 576 35 M. Mesías, M. Navarro, V. Gökmen and F. J. Morales, Antiglycative effect of fruit and
577 vegetable seed extracts: inhibition of AGE formation and carbonyl-trapping abilities, *J. Sci.*
578 *Food Agric.*, 2013, 93, 2037-2044.
- 579 36 W. Sompong, A. Meeprom, H. Cheng and S. Adisakwattana, A comparative study of ferulic acid
580 on different monosaccharide-mediated protein glycation and oxidative damage in bovine serum
581 albumin, *Molecules*, 2013, 18, 13886-13903.
- 582 37 L. S. Zhang, X. Wang and L. L. Dong, Antioxidation and antiglycation of polysaccharides from
583 *Misgurnus anguillicaudatus*, *Food Chem.*, 2011, 124, 183-187.

- 584 38 Y. Xu, G. Liu, Z. Yu, X. Song, X. Li, Y. Yang, L. Wang, L. Liu and J. Dai, Purification,
585 characterization and antiglycation activity of a novel polysaccharide from black currant, *Food*
586 *Chem.*, 2016, 199, 694-701.
- 587 39 A. Papetti, M. Daglia, C. Aceti, M. Quaglia, C. Gregotti and G. Gazzani, Isolation of an *in vitro*
588 and *ex vivo* antiradical melanoidin from roasted barley, *J. Agric. Food Chem.*, 2006, 54, 1209–
589 1216.
- 590 40 C. Delgado-Andrade and F. J. Morales, Unraveling the contribution of melanoidins to the
591 antioxidant capacity of coffee brew, *J. Agric. Food Chem.*, 2005, 53, 1403-1407.
- 592 41 M. M. Natić, D. Č. Dabić, A. Papetti, M. M. Fotirić Akšić, V. Ognjanov, M. Ljubojević and Ž.
593 Tešić, Analysis and characterisation of phytochemicals in mulberry (*Morus alba* L.) fruits
594 grown in Vojvodina, North Serbia, *Food Chem.*, 2015, 171, 128-136.
- 595 42 F. Ferreres, B. M. Silva, P. B. Andrade, R. M. Seabra and M. A. Ferreira, Approach to the study
596 of C-glycosyl flavones by ion trap HPLC-PAD-ESI/MS/MS: application to seeds of Quince
597 (*Cydonia oblonga*), *Phytochem. Anal.*, 2003, 14, 352-359.
- 598 43 S. Galasso, S. Pacifico, N. Kretschmer, S-P. Pan, S. Marciano, S. Piccolella, P. Monaco and R.
599 Bauer, Influence of seasonal variation on *Thymus longicaulis* C. Presl chemical composition and
600 its antioxidant and anti-inflammatory properties, *Phytochem.*, 2014, 107, 80-90.
- 601 44 A. R. Bilia, M. Giomi, M. Innocenti, S. Gallori and F. F. Vincieri, HPLC-DAD-ESI-MS analysis
602 of the constituents of aqueous preparations of verbena and lemon verbena and evaluation of the
603 antioxidant activity, *J. Pharm. Biomed. Anal.*, 2008, 46, 463-470.
- 604 45 S. Rehecho, O. Hidalgo, M. García-Iñiguez De Cirano, I. Navarro, I. Astiasarán, D. Ansorena, R.
605 Y. Cavero and M. I. Calvo, Chemical composition, mineral content and antioxidant activity of
606 *Verbena officinalis* L. *LWT, Food Sci. Technol.*, 2011, 44, 875-882.
- 607 46 A. Taamalli, D. Arráez-Román, L. Abaza, I. Iswaldi, A. Fernández-Gutiérrez, M. Zarrouk and A.
608 Segura-Carretero, LC-MS-based metabolite profiling of methanolic extracts from the medicinal

- 609 and aromatic species *Mentha pulegium* and *Origanum majorana*, *Phytochem. Anal.*, 2015, 26,
610 320-330.
- 611 47 A. R. Bilia, M. Giomi, M. Innocenti, S. Gallori and F. F. Vincieri, HPLC-DAD-ESI-MS analysis
612 of the constituents of aqueous preparation of verbena and lemon verbena and evaluation of the
613 antioxidant activity, *J. Pharm. Biomed. Anal.*, 2008, 46, 463-470.
- 614 48 S. Rehecho, O. Hidalgo, M. García-Iñiguez de Cirano, I. Navarro, I. Astiasarán, D. Ansorena, R.
615 Y. Cavero and M. I. Calvo, Chemical composition, mineral content and antioxidant activity of
616 *Verbena officinalis* L., *LWT-Food Sic. Technol.*, 2011, 44, 875-882.
- 617 49 M. Skoula, R. J. Grayer, G. C. Kite and N. C. Veitch, Exudate flavones and flavanones in
618 *Origanum* species and their interspecific variation, *Biochem. Syst. Ecol.*, 2008, 36, 646-654.
- 619 50 M. Hossain, D. Rai, N. Brunton, A. B. Martin-Diana and C. Barry-Ryan, Characterization of
620 phenolic composition in Lamiaceae spices by LC-ESI-MS/MS, *J. Agric. Food Chem.*, 2010, 58,
621 10576-10581.
- 622 51 G. Kouri, D. Tsimogiannis, H. Bardouki and V. Oreopoulou, Extraction and analysis of
623 antioxidant components from *Origanum dictamnus*, *Inn. Food Sci. Emerg. Technol.*, 2007, 8,
624 155-162.
- 625 52 B. Boros, S. Jakabová, Á. Dörnyei, G. Horváth, Z. Pluhár, F. Kilar and A. Felinger,
626 Determination of polyphenolic compounds by liquid chromatography-mass spectrometry in
627 *Thymus* species, *J. Chromatogr. A*, 2010, 1217, 7972-7980.
- 628 53 U. Justesen, Negative atmospheric pressure chemical ionization low-energy collision activation
629 mass spectrometry for the characterization of flavonoids in extracts of fresh herbs, *J.*
630 *Chromatogr. A*, 2000, 902, 369-379.
- 631 54 Y. Lu and L. Y. Foo, Salvianolic acid L, a potent phenolic antioxidant from *Salvia officinalis*,
632 *Tetrahedron Lett.*, 2001, 42, 8223-8225.
- 633 55 V. Exarchou, P. G. Takis, M. Malouta, J. Vervoort, E. Karali and A. N. Troganis. Four new
634 depsides in *Origanum dictamnus* methanol extract. *Phytochem. Lett.*, 2013, 6, 46-52.

- 635 56 A. H. Liu, Y. H. Lin, M. Yang, H. Guo, S. H. Guan, J. H. Sun and D. A. Guo, Development of
636 the fingerprints for the quality of the roots of *Salvia miltiorrhiza* and its related preparations by
637 HPLC-DAD and LC-MSⁿ, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2007, 846, 32-
638 41.
- 639 57 S. Wang, L. Liu, L. Wang, Y. Hu, W. Zhang and R. Liu, Structural characterization and
640 identification of major constituents in Jitai tablets by high-performance liquid
641 chromatography/diode-array detection coupled with electrospray ionization tandem mass
642 spectrometry, *Molecules*, 2012, 17, 10470-10493.
- 643 58 N. Martins, L. Barros, C. Santos-Buelga, M. Henriques, S. Silva and I. C. Ferreira, Decoction,
644 infusion and hydroalcoholic extract of *Origanum vulgare* L.: different performances regarding
645 bioactivity and phenolic compounds, *Food Chem*, 2014, 158, 73-80.
- 646 59 M. Ruan, Y. Li, X. Li, J. Luo and L. Kong, Qualitative and quantitative analysis of the major
647 constituents in Chinese medicinal preparation Guan-Xin-Ning injection by HPLC-DAD-ESI-
648 MSⁿ, *J. Pharm. Biomed. Anal.*, 2012, 59, 184-189.
- 649 60 J. Zhu, X. Yi, J. Zhang, S. Chen and Y. Wu, Chemical profiling and antioxidant evaluation of
650 Yangxinshi Tablet by HPLC-ESI-Q-TOF-MS/MS combined with DPPH assay, *J. Chromatogr.*
651 *B*, 2017, 1060, 262-271.
- 652 61 C. Koukoulitsa, A. Karioti, M. C. Bergonzi, G. Pescitelli, L. Di Bari and H. Skaltsa, Polar
653 constituents from the aerial parts of *Origanum vulgare* L. Ssp. *hirtum* growing wild in Greece, *J.*
654 *Agric. Food Chem.*, 2006, 54, 5388-5392.
- 655 62 O. Pereira, A. Peres, A. Silva, M. Domingues and S. Cardoso, Simultaneous characterization and
656 quantification of phenolic compounds in *Thymus x citriodorus* using a validated HPLC-UV
657 combined method, *Food Res. Int.*, 2013, 54, 1773-1780.
- 658 63 J. W. Baynes, N. G. Watkins, C. I. Fisher, C. J. Hull, J. S. Patrick, M. U. Ahmed, J. A. Dunn and
659 S. R. Thorpe, The Amadori product on protein: structure and reactions, *Prog. Clin. Biol*, 1989,
660 304, 43-67.

- 661 64 I. Sadowska-Bartosz, S. Galiniak and G. Bartosz, Kinetics of glycoxidation of bovin serum
662 albumin by glucose, fructose and ribose and its prevention by food components, *Molecules*,
663 2014, 19, 18828-18849.
- 664 65 Y. Wei, L. Chen, J. Chen, L. Ge and R. Q. He, Rapid glycation with D-ribose induces globular
665 amyloid-like aggregation of BSA with high cytotoxicity to SH-SY5Y cells, *BMC Cell Biol.*,
666 2009, 10, 10.
- 667 66 M. Maietta, R. Colombo, R. La Vecchia, M. Sorrenti, A. Zuorro and A. Papetti, Artichoke
668 (*Cynara cardunculus* L. var. *scolymus*) waste as a natural source of carbonyl trapping and
669 antiglycative agents, *Food Res. Int.*, 2017, 100, 780-790.
- 670 67 S.-C. Ho, S.-P. Wu, S.-M. Lin and Y.-L. Tang, Comparison of anti-glycation capacities of
671 several herbal infusions with that of green tea, *Food Chem.*, 2012, 122, 768-774.
- 672 68 P. Deetae, P. Parichanon, P. Trakunleewatthana, C. Chanseetis and S. Lertsiri, Antioxidant and
673 anti-glycation properties of Thai herbal teas in comparison with conventional teas, *Food*
674 *Chem.*, 2012, 133, 953-959.
- 675 69 N. Lunceford and A. Gugliucci, *Ilex paraguariensis* extracts inhibit AGE formation more
676 efficiently than gree tea, *Fitoterapia*, 2005, 76, 419-427.
- 677 70 J.-W. Wu, C.-L. Hsieh, H.-Y. Wang and H.-Y. Chen, Inhibitory effects of guava (*Psidium*
678 *guajava* L.) leaf extracts and its active compounds on the glycation process of protein, *Food*
679 *Chem.*, 2009, 113, 78-84.
- 680 71 Y. Bains and A. Gugliucci, *Ilex paraguariensis* and its main component chlorogenic acid inhibit
681 fructose formation of advanced glycation endproducts with amino acids at conditions
682 compatible with those in the digestive system, *Fitoterapia*, 2017, 117, 6-10.
- 683 72 Y. Xie and X. Chen, Structures required of polyphenols for inhibiting advanced glycation end
684 products formation, *Curr. Drug Metab.*, 2013, 14, 414-431.
- 685

686 **Table 1.** Antioxidant activity of dittany infusion. The results are expressed as mean \pm DS for $n=6$.

687

688

| $\mu\text{mol g}^{-1}$ | Dittany infusion |
|------------------------|------------------|
| ABTS TEAC | 2.8 ± 0.3 |
| DPPH TEAC | 177.1 ± 1.5 |
| Reducing power | 308.6 ± 3.4 |

689
690
691
692
693
694
695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

Table 2. MS, MS/MS, and MS³ data (negative and positive ionization modes) of the compounds identified in dittany infusion (Compounds are reported in order of elution; ^a positive ionization mode; *compared with standard compounds).

| Compound | Precursor ion (<i>m/z</i>) | HPLC-ESI/MS ^a <i>m/z</i> (% of base peak) | Compound identity |
|----------|---------------------------------|---|--|
| 1 | 327 | MS ² [327]: 165(100), 121(25) | <i>p</i> -hydroxyphenylpropionic acid hexoside |
| 2 | 387 | MS ² [387]: 369(30), 207(100), 163(90) MS ³ [207]: 163(100) | 12-Hydroxyjasmonic acid <i>O</i> -hexoside |
| 3 | 593 | MS ² [593]: 473(100), 383(35), 353(70), 279(5) | 6,8-di- <i>C</i> -hexosylapigenin |
| 4 | 305 | MS ² [305]: 225(100), 97(50) | Gallocatechin* |
| 5 | 797 | MS ² [797]: 527(100), 351(50), 269(12) | Apigenin- <i>O</i> -triglucuronide isomer 1 |
| 6 | 637 | MS ² [637]: 351(100), 285(40) | Luteolin-7- <i>O</i> -diglucuronide |
| 7 | 813 | MS ² [813]: 527(100), 351(60), 285(20) | Kaempferol- <i>O</i> -triglucuronide isomer 1 |
| 8 | 797 | MS ² [797]: 527(100), 351(60), 269(15) | Apigenin- <i>O</i> -triglucuronide isomer 2 |
| 9 | 621 | MS ² [621]: 351(100), 269(10) | Apigenin-7- <i>O</i> -diglucuronide |
| 10 | 359 | MS ² [359]: 197(20), 179(25), 161(100) | Rosmarinic acid* |
| 11 | 537 | MS ² [537]: 493(100), 295(25) | Lithospermic acid |
| 12 | 555 | MS ² [555]: 493(100), 359(20) | Salvianolic acid K |
| 13 | 445 | MS ² [445]: 269(100) | Apigenin-7- <i>O</i> -glucuronide* |
| 14 | 593 | MS ² [593]: 286(60), 285(100) | Luteolin-7- <i>O</i> -rutinoside* |
| 15 | 813 | MS ² [813]: 527(100), 351(55), 285(40) | Kaempferol- <i>O</i> -triglucuronide isomer 2 |
| 16 | 345 ^a | MS ² [345]: 330(100), 315(55), 313(50) | 5,4'-dihydroxy-6,7,8-trimethoxyflavone |
| 17 | 717 | MS ² [717]: 519(100), 475(50), 339(30), 321(30) | Salvianolic acid B |
| 18 | 537 | MS ² [537]: 493(100), 339(35), 313(15), 295(25) MS ³ [439]: 179(100) | Salvianolic acid I |
| 19 | 493 | MS ² [493]: 295(100), 185(75), 109(10) | Salvianolic acid A |
| 20 | 717 | MS ² [717]: 519(100), 475(40), 339(50) | Isosalvianolic acid B |

716

717

718

719 **Figure captions**

720 **Figure 1.** HPLC-DAD chromatogram of dittany infusion registered at 320 nm.

721 **Figure 2.** Inhibitory effect of dittany infusion on the formation of dicarbonyl compounds in BSA-
722 GLC (A), BSA-FRU (B), and BSA-RIB (C) systems.


723 **Figure 3.** Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of
724 vesperlysine-like AGEs in BSA-GLC assay. Different superscript letters within each monitoring
725 time indicate significant differences ($P < 0.05$) among AG and infusion.

726 **Figure 4.** Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of
727 vesperlysine-like AGEs in BSA-FRU assay. Different superscript letters within each monitoring
728 time indicate significant differences ($P < 0.05$) among AG and infusion.

729 **Figure 5.** Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of
730 (A) vesperlysine-like AGEs and (B) pentosidine-like AGEs in BSA-RIB assay. Different
731 superscript letters within each monitoring time indicate significant differences ($P < 0.05$) among
732 AG and infusion.


733 **Figure 6.** Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of
734 (A) vesperlysine-like AGEs and (B) argpyrimidine-like AGEs in BSA-MGO assay. Different
735 superscript letters within each monitoring time indicate significant differences ($P < 0.01$) among
736 AG and infusion.

737 **Figure 7.** Kinetic study of direct MGO (A) and GO (B) trapping capacity of dittany infusion after
738 incubation (0-168 h).




HPLC-DAD chromatogram of dittany infusion registered at 320 nm.

14x11mm (600 x 600 DPI)




Inhibitory effect of dittany infusion on the formation of dicarbonyl compounds in BSA-GLC (A), BSA-FRU (B), and BSA-RIB (C) systems.

22x34mm (600 x 600 DPI)





Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of vesperlysine-like AGEs in BSA-GLC assay. Different superscript letters within each monitoring time indicate significant differences ($P < 0.05$) among AG and infusion.

14x11mm (600 x 600 DPI)





Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of vesperlysine-like AGEs in BSA-FRU assay. Different superscript letters within each monitoring time indicate significant differences ($P < 0.05$) among AG and infusion.

14x11mm (600 x 600 DPI)




Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of (A) vesperlysine-like AGEs and (B) pentosidine-like AGEs in BSA-RIB assay. Different superscript letters within each monitoring time indicate significant differences ($P < 0.05$) among AG and infusion.

19x26mm (600 x 600 DPI)



Antiglycative activity of dittany infusion and aminoguanidine (AG) on the formation of (A) vesperlysine-like AGEs and (B) argpyrimidine-like AGEs in BSA-MGO assay. Different superscript letters within each monitoring time indicate significant differences ($P < 0.01$) among AG and infusion.

19x26mm (600 x 600 DPI)



Kinetic study of direct MGO (A) and GO (B) trapping capacity of dittany infusion after incubation (0-168 h).

14x11mm (600 x 600 DPI)